These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12820814)

  • 1. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies.
    Etminan M; Gill S; Samii A
    Pharmacotherapy; 2003 Jun; 23(6):726-30. PubMed ID: 12820814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive LDL-cholesterol lowering therapy and neurocognitive function.
    Banach M; Rizzo M; Nikolic D; Howard G; Howard V; Mikhailidis D
    Pharmacol Ther; 2017 Feb; 170():181-191. PubMed ID: 27865998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations.
    Rojas-Fernandez CH; Cameron JC
    Ann Pharmacother; 2012 Apr; 46(4):549-57. PubMed ID: 22474137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum lipoprotein levels, statin use, and cognitive function in older women.
    Yaffe K; Barrett-Connor E; Lin F; Grady D
    Arch Neurol; 2002 Mar; 59(3):378-84. PubMed ID: 11890840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline characteristics, analysis plan and report on feasibility for the Prevention Of Decline in Cognition After Stroke Trial (PODCAST).
    Scutt P; Blackburn D; Krishnan K; Ballard C; Burns A; Ford GA; Mant J; Passmore P; Pocock S; Reckless J; Sprigg N; Stewart R; Wardlaw JM; Bath PM
    Trials; 2015 Nov; 16():509. PubMed ID: 26545986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bi-directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose-lowering agents: a systematic review and meta-analysis.
    Mattishent K; Loke YK
    Diabetes Obes Metab; 2016 Feb; 18(2):135-41. PubMed ID: 26446922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease.
    McGuinness B; Todd S; Passmore P; Bullock R
    Cochrane Database Syst Rev; 2006 Apr; (2):CD004034. PubMed ID: 16625595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms.
    Rouch L; Cestac P; Hanon O; Cool C; Helmer C; Bouhanick B; Chamontin B; Dartigues JF; Vellas B; Andrieu S
    CNS Drugs; 2015 Feb; 29(2):113-30. PubMed ID: 25700645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?
    Gaist D; García Rodríguez LA; Huerta C; Hallas J; Sindrup SH
    Eur J Clin Pharmacol; 2001 Mar; 56(12):931-3. PubMed ID: 11317483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-lowering agents for nephrotic syndrome.
    Kong X; Yuan H; Fan J; Li Z; Wu T; Jiang L
    Cochrane Database Syst Rev; 2013 Dec; (12):CD005425. PubMed ID: 24327265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins, fibrates, and venous thromboembolism: a meta-analysis.
    Squizzato A; Galli M; Romualdi E; Dentali F; Kamphuisen PW; Guasti L; Venco A; Ageno W
    Eur Heart J; 2010 May; 31(10):1248-56. PubMed ID: 20031958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of lipid-lowering agents for the prevention of age-related macular degeneration: a meta-analysis of observational studies.
    Chuo JY; Wiens M; Etminan M; Maberley DA
    Ophthalmic Epidemiol; 2007; 14(6):367-74. PubMed ID: 18161610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases.
    Corrao G; Zambon A; Bertù L; Botteri E; Leoni O; Contiero P
    J Epidemiol Community Health; 2004 Dec; 58(12):1047-51. PubMed ID: 15547071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials.
    Ott BR; Daiello LA; Dahabreh IJ; Springate BA; Bixby K; Murali M; Trikalinos TA
    J Gen Intern Med; 2015 Mar; 30(3):348-58. PubMed ID: 25575908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid with or without vitamin B12 for cognition and dementia.
    Malouf M; Grimley EJ; Areosa SA
    Cochrane Database Syst Rev; 2003; (4):CD004514. PubMed ID: 14584018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis.
    Upadhyay A; Earley A; Lamont JL; Haynes S; Wanner C; Balk EM
    Ann Intern Med; 2012 Aug; 157(4):251-62. PubMed ID: 22910936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study.
    Gaist D; Rodríguez LA; Huerta C; Hallas J; Sindrup SH
    Epidemiology; 2001 Sep; 12(5):565-9. PubMed ID: 11505177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
    Graham DJ; Staffa JA; Shatin D; Andrade SE; Schech SD; La Grenade L; Gurwitz JH; Chan KA; Goodman MJ; Platt R
    JAMA; 2004 Dec; 292(21):2585-90. PubMed ID: 15572716
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.